Plain-English translation of NCT07263178 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This is an observational study โ meaning researchers will watch and document what happens naturally as you receive treatment for advanced colorectal cancer that has spread to other parts of your body. The study focuses on second-line chemotherapy, which is the treatment you receive when your first chemotherapy is no longer working. Researchers want to understand which second-line treatments doctors choose most often and how well they work for patients like you.
Advanced colorectal cancer often requires more than one round of chemotherapy as the cancer becomes resistant to the first treatment. By tracking real-world treatment patterns and outcomes across many hospitals, researchers hope to better understand which second-line approaches work best and improve care for future patients.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will continue your regular medical care and chemotherapy appointments as usual โ this study does not change your treatment plan. Researchers will collect information from your medical records about which chemotherapy you receive, how your cancer responds, and how you tolerate the medication. They will track your progress over time to build a clear picture of real-world treatment patterns and patient outcomes at multiple hospitals.
AI-generated summary from trial data ยท Jul 18, 2026 ยท Not medical advice
South Korea
Sponsor
Boryung Pharmaceutical Co., Ltd
Enrollment target
~1,000 participants
Started
November 2025
Primary completion
December 2029
Age range
19 Years and older
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Shinyoung Oh
Boryung Pharmaceutical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.